Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Feasibility Study of Durvalumab (MEDI4736) and Tremelimumab Following Radioembolization in Patients With Metastatic Microsatellite Stable (MSS) Colorectal Cancer to the Liver

NCT03005002 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03005002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Feasibility Study of Durvalumab (MEDI4736) and Tremelimumab Following Radioembolization in Patients With Metastatic Microsatellite Stable (MSS) Colorectal Cancer to the Liver
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
June 28, 2017
Completion date
November 26, 2019
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic carcinoma in the liver, mlh1 gene mutation, msh6 gene mutation, pms2 gene mutation, stage iv colorectal cancer, stage iva colorectal cancer, stage ivb colorectal cancer